VEGFR1–mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy

VEGF coordinates complex regulation of cellular regeneration and interactions between endothelial and perivascular cells; dysfunction of the VEGF signaling system leads to retinopathy. Here, we show that systemic delivery of VEGF and placental growth factor (PlGF) by protein implantation, tumors, and adenoviral vectors ablates pericytes from the mature retinal vasculature through the VEGF receptor 1 (VEGFR1)-mediated signaling pathway, leading to increased vascular leakage. In contrast, we demonstrate VEGF receptor 2 (VEGFR2) is primarily expressed in nonvascular photoreceptors and ganglion cells. Moreover, blockade of VEGFR1 but not VEGFR2 significantly restores pericyte saturation in mature retinal vessels. Our findings link VEGF and PlGF to cancer-associated retinopathy, reveal the molecular mechanisms of VEGFR1 ligand-mediated retinopathy, and define VEGFR1 as an important target of antiangiogenic therapy for treatment of retinopathy.

[1]  H. Augustin,et al.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. , 2009, The Journal of clinical investigation.

[2]  Yihai Cao Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[3]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[4]  A. Hansen,et al.  Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome , 2008, Proceedings of the National Academy of Sciences.

[5]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[6]  M. Matsumura,et al.  Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. , 2008, Ophthalmology.

[7]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[8]  B. Perry,et al.  Tris (Dibenzylideneacetone) Dipalladium, a N-Myristoyltransferase-1 Inhibitor, Is Effective against Melanoma Growth In vitro and In vivo , 2008, Clinical Cancer Research.

[9]  K. Becker,et al.  VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. , 2008, The Journal of clinical investigation.

[10]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[11]  C. Focan,et al.  [Cancer associated retinopathy (CAR). Two clinical cases and review of the literature]. , 2007, Revue medicale de Liege.

[12]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[13]  E. Stone A very effective treatment for neovascular macular degeneration. , 2006, The New England journal of medicine.

[14]  J. Martin Collinson,et al.  Corneal avascularity is due to soluble VEGF receptor-1 , 2006, Nature.

[15]  A. Hansen,et al.  Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. , 2006, Blood.

[16]  C. Foster,et al.  Cancer Associated Retinopathy (CAR): An Autoimmune-Mediated Paraneoplastic Syndrome , 2006, Seminars in ophthalmology.

[17]  I. Zachary Neuroprotective Role of Vascular Endothelial Growth Factor: Signalling Mechanisms, Biological Function, and Therapeutic Potential , 2005, Neurosignals.

[18]  Jean-Michel Foidart,et al.  Pegaptanib and age-related macular degeneration. , 2005, The New England journal of medicine.

[19]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[20]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[21]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[22]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[23]  Yihai Cao,et al.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.

[24]  Xuri Li,et al.  Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. , 2001, The international journal of biochemistry & cell biology.

[25]  Xuri Li,et al.  Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors , 2001, Growth factors.

[26]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[27]  A. Milam,et al.  Cancer-associated retinopathy. , 1999, Archives of ophthalmology.

[28]  Patrick W. Faloon,et al.  In vitro hematopoietic and endothelial potential of flk-1(-/-) embryonic stem cells and embryos. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[30]  J. Folkman,et al.  In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. , 1996, The Journal of clinical investigation.

[31]  K. Hirschi,et al.  Pericytes in the microvasculature. , 1996, Cardiovascular research.

[32]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[33]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[34]  A. Roth,et al.  Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. , 1989, The New England journal of medicine.

[35]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[36]  S. Buzney,et al.  Retinal capillaries: proliferation of mural cells in vitro , 1975, Science.

[37]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[38]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[39]  H. Wilhelm,et al.  [Carcinoma-associated retinopathy: a review with clinical examples]. , 2000, Klinische Monatsblatter fur Augenheilkunde.

[40]  H. Wilhelm,et al.  Karzinomassoziierte Retinopathie: Eine Übersicht mit klinischen Beispielen , 2000 .

[41]  P. De Potter,et al.  Ocular manifestations of cancer. , 1998, Current opinion in ophthalmology.